Upstream Bio, Inc. (UPB)

Upstream Bio, Inc.'s stock price has experienced volatility and a downtrend in the past six months, decreasing by 47.99%. A sharp decline occurred in February 2026 after the release of Phase 2 VALIANT trial results, raising concerns about the competitive positioning of verekitug. This led to analyst downgrades, although the consensus rating remains a "Moderate Buy". The company also reported a wider net loss in Q4 2025 due to increased research and development expenses.

As a clinical-stage biotechnology company, Upstream Bio, Inc. is primarily focused on research, development, and clinical trials, rather than commercial sales. Therefore, there is no information available regarding demand seasonality for Upstream Bio, Inc.'s products or services, as it does not currently have commercialized products.

Upstream Bio, Inc. is a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders. Their lead product candidate, verekitug (UPB-101), is a monoclonal antibody targeting TSLP. Verekitug is in Phase 2 trials for severe asthma (VALIANT study), which showed statistically significant reductions in asthma exacerbations, and Phase 2 trials for chronic rhinosinusitis with nasal polyps (CRSwNP) (VIBRANT study), which met its primary endpoint. Additionally, it is in an ongoing Phase 2 clinical trial for chronic obstructive pulmonary disease (COPD) (VENTURE study).

Upstream Bio, Inc. is headquartered in Waltham, Massachusetts, United States. The company conducts global clinical trials, indicating an international reach in its clinical development activities.

Information specifically detailing Upstream Bio, Inc.'s brand reputation in terms of public image or patient/physician perception is not readily available. The available data primarily focuses on investor sentiment, analyst ratings, and stock performance, which are related to financial reputation rather than a broader brand reputation. Analyst ratings for UPB are generally positive, with a consensus of "Moderate Buy" and a high average price target, despite recent stock price declines and downgrades from some firms.

Upstream Bio, Inc. has significant institutional ownership, with 133 institutional owners and shareholders holding a total of 50,340,368 shares, representing approximately 63.57% to 94.04% of the company's stock. Major institutional owners include Fmr Llc, Orbimed Advisors Llc, and BlackRock, Inc. The largest individual shareholder is Erez Chimovits, owning 5.81 million shares, representing 10.68% of the company. Insiders collectively hold approximately 8.75% to 33.43% of the stock.